Multiple Sclerosis News Today Covers Stem Cell Institute Clinical Trial for MS

[fusion_imageframe image_id=”6050″ style_type=”none” stylecolor=”” hover_type=”none” bordersize=”” bordercolor=”” borderradius=”” align=”none” lightbox=”no” gallery_id=”” lightbox_image=”” alt=”Image of GMP syringe prep lab at Stem Cell Institute clinic in Panama.” link=”” linktarget=”_self” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” animation_type=”” animation_direction=”left” animation_speed=”0.3″ animation_offset=””]https://www.cellmedicine.com/wp-content/uploads/2018/04/IMG_3007-600×450.jpg[/fusion_imageframe]

Stem cells being prepared for treatment.

Multiple Sclerosis News Today has published an article entitled “Treatment with Umbilical Cord Stem Cells Safe with Sustained Benefits for MS, Trial Shows“. This article can be read in its entirely at MultipleSclerosisNewsToday.com.

The name of the study, which is published in the Journal of Translational Medicine, is “Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis”.

The study concluded that “…intravenous infusion of UCMSC over several days is safe in subjects with MS. Additionally, UCMSC infusions may hold benefits, since this small study group saw improvement in bladder, bowel, and sexual dysfunction, walking, upper extremity physical function, energy and fatigue, general perspective of a positive health change and improved quality of life, and MRI lesions. More clinical studies, particularly with a larger cohort, are needed to substantiate the specific benefits of UCMSC infusion as a potential MS therapy.”